Editas Medicine (EDIT) Cash & Current Investments (2015 - 2025)

Editas Medicine (EDIT) has reported Cash & Current Investments for 11 consecutive years, with $146.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Current Investments fell 45.67% year-over-year to $146.6 million; the TTM figure through Dec 2025 stood at $146.6 million (down 45.67% YoY), while the FY2025 annual figure was $146.6 million, down 45.67% from the prior year.
• Cash & Current Investments eased to $146.6 million in Q4 2025 per EDIT's latest filing, from $165.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $625.3 million in Q1 2021 and bottomed at $146.6 million in Q4 2025.
• Historically, Cash & Current Investments has averaged $362.2 million across 5 years, with a median of $333.7 million in 2022.
• Annual changes were most pronounced in 2021 — Cash & Current Investments jumped 50.69% — and 2025, when it plunged 45.67%.
• Editas Medicine's Cash & Current Investments stood at $499.8 million in 2021, then tumbled by 31.12% to $344.3 million in 2022, then decreased by 6.15% to $323.1 million in 2023, then fell by 16.46% to $269.9 million in 2024, then slumped by 45.67% to $146.6 million in 2025.
• Business Quant data shows EDIT's Cash & Current Investments at $146.6 million in Q4 2025, $165.6 million in Q3 2025, and $178.5 million in Q2 2025.